By Georges Mathé MD (auth.)

I wish to thank all my co-workers who've collaborated with me, from 1963 earlier, in organic and medical study within the box of melanoma lively immunotherapy, of its immuno­ prevention and immunorestoration. they're going to frequently be quoted during this publication. i'm rather thankful to those that have helped me to write down it via reviewing a few chapters: D. BELPOMME, J. F. DOR~, IRENE FLORENTIN, A. GOUTNER, I. J. Hm, R. HUCHET and MARIE-CHRISTINE SIMMLER. I additionally thank NICOLE VRIZ, MARIE-CLAUDE SCHNEIDER, FENELLARIsELEY and M. JUVET for his or her keen and effective co-operation within the preperation of the manuscript. i'm ultimately thankful to all authors of books or articles who approved me to breed their figures or tables. Paris, April 1976 G. MAT~ Contents bankruptcy 1. creation and Definitions 1 bankruptcy 2. organic foundation: Tumour linked Antigens, the Immune equipment and Its Behaviour pertaining to melanoma Cells five 2. 1. Tumour-Associated Antigens five 2. 2. The Immune equipment 19 2. 2. 1. Humoral Mediated Immunity and mobile Mediated Immunity 19 2. 2. 2. T- and B-Lymphocyte and Monocyte Differen­ tiation 22 2. 2. three. T-Lymphocyte features 25 2. 2. four. B-Lymphocyte features 30 2. 2. five. Macrophage features 31 2. 2. 6. K-Cell functionality 32 2. three. The Immune equipment and melanoma Cells 33 2. three. 1. Mechanisms fascinated about Tumour cellphone Rejec­ tion 33 2. three. 1. 1. In vivo proof for Tumour Immunity 33 2. three. 1. 2.

Show description

Read or Download Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration PDF

Similar cancer books

Brain - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

It is a 3-in-1 reference publication. It offers a whole clinical dictionary masking 1000s of phrases and expressions with regards to mind. It additionally offers wide lists of bibliographic citations. ultimately, it offers info to clients on how you can replace their wisdom utilizing numerous net assets. The ebook is designed for physicians, scientific scholars getting ready for Board examinations, clinical researchers, and sufferers who are looking to familiarize yourself with learn devoted to mind.

Antifolate Drugs in Cancer Therapy

In Antifolate medicinal drugs in melanoma treatment, Ann Jackman and a panel of very hot researchers comprehensively overview the present prestige of novel antifolates, a massive category of anticancer medicinal drugs. the celebrated individuals speak about the preclinical and scientific pharmacology of methotrexate, different dihydrofolate reductase inhibitors, 5-fluorouracil, and the hot iteration of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors.

Additional info for Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration

Example text

The blocking effect of cellular cytotoxicity observed in vitro with sera from tumourbearing hosts rapidly appeared as a more complex phenomenon as far as the nature of the blocking factors and their mode of action were concerned. The observation that blocking activity in the serum of tumour-bearing animals could be abrogated by precipitation with anti-immunoglobulin sera demonstrated that tumour specific antibodies were involved (HELLSTROM and HELLSTROM, 1969b). , 1973, 1973), strongly suggested that free antibodies were not resuming the blocking process.

SUC)pressor function Fig. 7. 1. Moc = Monocyte, 2. Nonactivated MpH = Nonactivated macrophage, 3. BLc = B-lymphocyte, 4 . Iic Tc = Immunoincompetent thymocyte, 5. Ic Tc = Immunocompetent thymocyte, 6. TLc = T-Iymphocyte, 6a. Hp TLc = "Helper" T-Iymphocyte, 6b. Sup. TLc = suppressor T-lymphocyte, 6c. Ef TLc = "Effector" T-lymphocyte, 6d. Amp TLc = "Amplifier" T-Iymphocyte, 7. T Imb = T immunoblast, 8. B Imb = B immunoblast, 9. Pc Plasma cell, 10. MBLc Memory B-Iymphocyte, 11. MTLc Memory T-lymphocyte, 12.

3. Role of T-Lymphocytes in Tumour Rejection Neonatal thymectomy increases the frequency of experimentally induced primary tumours (LAW, 1966; ALLISON and TAYLOR, 1967), suggesting that T-lymphocytes play an important part in the "defence" mechanisms against tumours. , 1972; GORCZYNSKI, 1974a). There is strong evidence that tumour-bearing host lymphocytes exert in vitro cytolytic and cytostatic effects on isogeneic or autochthonous tumour cells (PERLMANN and HOLH, 1969; HELL STROH and HELLSTROM, 1974b; CEROTTINI and BRUNNER, 1974; HERBERMAN, 1974) .

Download PDF sample

Cancer Active Immunotherapy: Immunoprophylaxis and by Georges Mathé MD (auth.)
Rated 4.51 of 5 – based on 32 votes